July 2026
INBRAIN and Microsoft Team Up on AI for Neurology and BCI
Barcelona-based INBRAIN Neuroelectronics said it will work with Microsoft on AI for neurology and brain-computer interfaces, combining INBRAIN's neuroscience, bioelectronics and AI work with Microsoft's cloud and AI infrastructure. INBRAIN's graphene-based neural interface is being developed as an adjunctive therapy for Parkinson's disease; it received FDA breakthrough device designation in 2023 and entered its first-in-human study in the fall of 2025.
INBRAIN and Microsoft Partner on AI for Real-Time BCI Adaptation
INBRAIN Neuroelectronics has announced a partnership with Microsoft to apply the software company's large language models and data analytics tools to make its brain-computer interfaces adapt in real time. INBRAIN builds graphene-electrode BCIs for neurological disorders, spanning invasive and non-invasive applications, and recently partnered with the Mayo Clinic to speed clinical development and commercialization of its BCI therapies, with investigator-led clinical research under way.
Microsoft and INBRAIN Neuroelectronics Partner on AI-Driven BCI Therapeutics
Microsoft and INBRAIN Neuroelectronics said they will work together on AI-driven brain-computer interface therapeutics, pairing INBRAIN's graphene-based neural interfaces with Microsoft's cloud computing and data infrastructure to speed development of treatments for neurological disorders. INBRAIN, a Spanish neurotechnology company, says its system combines graphene electrodes with AI algorithms to read and modulate brain signals with high precision, on a platform it describes as bringing together neuroscience, bioelectronics and AI.
June 2026
OYMotion and MicroPort NeuroScientific Partner on Endovascular BCI Rehab System
OYMotion and MicroPort NeuroScientific signed a strategic cooperation agreement on May 28, 2026 to jointly develop an interventional brain-computer interface rehabilitation system. The first product will be a multi-channel endovascular BCI that threads a signal-recording stent through the blood vessels to a target brain region, capturing intracranial electrical activity without opening the skull. MicroPort NeuroScientific will build the BCI system as a whole and OYMotion the limb side, with the pair targeting medical rehabilitation and human-machine interaction.
NeuroXess Says Two Paralyzed Patients Played Brain-Controlled Chess 800 km Apart
April 2026
China Hubei Approves a Provincial BCI Innovation Centre Led by a Hospital
On 31 March 2026 Hubei's provincial science and technology department approved the formation of a provincial brain-computer interface technology innovation centre, led by Tongji Hospital in Wuhan together with 12 organisations including Huazhong University of Science and Technology and Hubei Optics Valley Laboratory. Chinese reports describe it as the country's first provincial BCI platform positioned as comprehensive and full-chain. Its stated priorities are neural signal decoding, domestic sourcing of core components, and refining both non-invasive and implanted approaches. It is headed by Tang Zhouping, the hospital's party secretary.
January 2026
NeuroXess Breaks Ground on BCI Factory Targeting 10,000-Unit Supply
NeuroXess broke ground on a roughly 14,300-square-meter BCI manufacturing project in Jiangxi province in eastern China. The company said the facility would produce flexible implantable electrodes, neural recording equipment, surgical robots and fully implanted wireless BCI systems, with a target of stable supply at the 10,000-unit scale. NeuroXess expects the factory to begin operating in the second half of 2026, but the capacity and timeline remain company projections.
September 2025
Chinese Hospital Opens Its Own Brain-Computer Interface Research Institute
Tongji Hospital in Wuhan announced a brain-computer interface research institute on 5 September 2025, which it says is the first of its kind run by a hospital in China rather than by a university or a company. The institute covers basic research, clinical application and commercialisation, with the stated aim of building a full-chain BCI system spanning prevention, diagnosis, treatment and rehabilitation of neurological disease.